Crossed from claiming to demonstrating: management marks its own before/after line with repeated, recent proof
The model's full reasoning — Q4 2021 call → NOWe need to determine if management conveys a recent crossing from claiming to demonstrating a capability, with repeated real events, and management drawing the before/after contrast. Let's examine the transcript for such a crossing. Key areas: HRD solution, CarePath, DEEP-Lung-IV study, biopharma partnerships, U.S. expansion, etc. Look for management's own words contrasting past claims with current reality, with repeated instances. For example, Jurgi mentions: "We are pleased with our progress off onboarding clinical customers in this region and are expecting several signed agreements with Tier 1 institutions in the coming months." That's future. Peter Casasanto talks about biopharma: "We are actually having these exact conversations with biopharma right now." That's ongoing but not necessarily a crossing. What about HRD? Jurgi says: "SOFIVA GENOMICS found great success while implementing our solution in a clinical setting for advanced HRD detection powered by the deep learning algorithms embedded in our classroom." That's a single event? Actually they mention multiple customers: "we recently signed new customers in Japan, South Korea, Singapore, and Hong Kong." But that's about oncology applications, not specifically HRD. The AstraZeneca partnership: "we recently announced the partnership with AstraZeneca to expand access to in-house HRD testing across European laboratories and institutions." That's a partnership, not yet repeated activity. CarePath: "We are extremely excited about this product and believe it will further differentiate SOPHiA as a tech company." That's future. DEEP-Lung-IV: "Since launching the study in November, 16 sites across six countries have signed up to participate." That's a study, not a commercial capability. It's a clinical study to validate predictive model. The after-side is that they have enrolled hundreds of patients, but it's still a study, not a proven capability.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
DXCM · Q4 2023 → YESThe question is about whether management conveys that the company has recently crossed from claiming something to demonstrating it. YES The transcript shows management drawing a clear before/after contrast on the Malaysia manufacturing facility: previously they relied on established US facilities, but mid-year they opened a new site and are now ramping production with yields matching the US ones—real, repeated activity rather than a single event or plan. This is framed as 2023 being transformational, with the new capability already contributing to results and positioned for further scaling ahead. The primary-care expansion also fits as a demonstrated shift from long-term investment to immediate results (70% of new scripts), but the manufacturing crossing is the clearest match to the criteria.
LC · Q4 2021 → YESThe question is about whether management conveys that the company has recently crossed from claiming something to demonstrating it. YES The transcript shows management drawing a clear before/after line: Scott Sanborn describes closing 2021 in the strongest position after executing a strategy laid out in February, creating America's first digital marketplace bank; Tom Casey states the radical transformation over the last year is now complete as promised, contrasting it with 2019 4Q revenue and net income levels to highlight the fundamental change. The after-side is real and repeated—record revenue, doubled economics, NII recurring stream, multiple quarters of strong performance—backed by actual bank operations and deliveries.
KTB · Q3 2021 → YESThe question is about whether management conveys that the company has recently crossed from claiming something to demonstrating it. YES Management draws its own before/after line in Scott Baxter’s opening remarks: “we are doing things with both the Wrangler and Lee brands that we have simply never done before,” directly contrasting past practice with the current reality of new marketing campaigns (Lee launched October, Wrangler September). The after-side is 1) real and recent (Q3 results show 50 % growth in U.S. outdoor and 60 % growth in work wear versus 2019 baselines) and 2) repeated across multiple categories and brands, confirming the capability is now operating rather than a one-off event.